

SUPPLEMENTAL MATERIAL

Nicotine exacerbates atherosclerosis and plaque instability via NLRP3 inflammasome activation in vascular smooth muscle cells

Junqing An[#], Liu Ouyang[#], Changjiang Yu, Sean Michael Carr, Tharmarajan Ramprasath, Zhixue Liu, Ping Song, Ming-Hui Zou, Ye Ding^{*}

Center for Molecular and Translational Medicine, Georgia State University, 157 Decatur Street SE, Atlanta, GA 30303

Supplemental Figures

Supplemental Figure 1




Figure S1. Red blood cells in atherosclerotic plaques. Representative immunohistochemistry staining of Ter119 for red blood cells and quantification of hemorrhage incidence in BA of *Apoe*^{-/-} mice with vehicle or nicotine infusion. Scale bar: 50 µm. Veh, vehicle; Nic, nicotine.

Supplemental Figure 2




Figure S2. The effect of nicotine on inflammasome activation in macrophages, T cells and endothelial cells. (A-B), Immunofluorescence staining and quantification of CD68 and Cat-B, NLRP3, ASC, or IL-1 β in BA of *Apoe*^{-/-} mice with vehicle or nicotine infusion. N=5. Scale bar: 50 μ m. (C&D), Immunofluorescence staining and quantification of CD3 and Cat-B, NLRP3, ASC, or IL-1 β in BA of *Apoe*^{-/-} mice with vehicle or nicotine infusion. N=5. Scale bar: 50 μ m. (E-F),

Immunofluorescence staining and quantification of CD31 and Cat-B, NLRP3, ASC, or IL-1 β in BA of *Apoe*^{-/-} mice with vehicle or nicotine infusion. N=4. Scale bar: 50 μ m. Cat B: Cathepsin B. Veh, vehicle; Nic, nicotine. Values represent the mean \pm SEM. **P*<0.05 vs Veh.

Supplemental Figure 3




Figure S3. TXNIP deletion in smooth muscle cells improves α -SMA expression in nicotine-induced atherosclerosis and plaque vulnerability. (A) Representative images of immunofluorescence staining of α -SMA (SM α -actin) in BA of *Apoe*^{-/-}*Txnip*^{SM22 α +/+} and *Apoe*^{-/-}*Txnip*^{SM22 α -/-} mice infused with nicotine. (B) Quantification of plaque SM α -actin coverage on the plaque cap in BA of *Apoe*^{-/-}*Txnip*^{SM22 α +/+} and *Apoe*^{-/-}*Txnip*^{SM22 α -/-} mice infused with nicotine. (C) Quantification of total plaque SM α -actin content in BA of *Apoe*^{-/-}*Txnip*^{SM22 α +/+} and *Apoe*^{-/-}*Txnip*^{SM22 α -/-} mice infused with nicotine. N=10. Scale bar: 100 μ m. Values represent the mean \pm SEM. **P*<0.05 vs *Apoe*^{-/-}*Txnip*^{SM22 α +/+}. Veh, vehicle; Nic, nicotine.

Supplemental Figure 4




Figure S4. Nicotine did not increase inflammatory cytokine IL-1 β in macrophage and HUVEC. (A-B) Western blot analysis of IL-1 β in nicotine (0.5 μ M) treated macrophage Raw264.7 (A) and HUVECs (B) for 24 hours. 100 ng/mL LPS served as control. Nic, nicotine.

Supplemental Figure 5




Figure S5. The effects of nicotine on inflammatory cytokine IL-1 β in THP-1 and HAEC. (A) Western blot analysis and quantification of IL-1 β release in nicotine (0.5 μ M for 24 h) treated THP-1 cells. N=3. (B) Western blot analysis and quantification of IL-1 β release in nicotine (0.5 μ M for 24 h) treated human aortic endothelial cells (HAoECs). N=6. (C) Relative increased fold of mL-1 β in HAoECs and VSMCs. N=6. 100 ng/mL LPS for 24 hours served as control. Values represent the mean \pm SEM. * P <0.05 vs Veh. Veh, vehicle; Nic, nicotine.

Supplemental Figure 6




Figure S6. Lysosomal acidification inhibitor NH₄Cl further increased mIL-1β secretion both in cell lysis and cell culture medium induced by nicotine. VSMCs were treated with nicotine (0.5 μM for 24 h) together with or without NH₄Cl (20 mM for 24 h). Western blot analysis of IL-1β. Values represent the mean ± SEM. **P*<0.05 vs. Veh-Con. †*P*<0.05 vs Nic-Con. Veh, vehicle; Nic, nicotine.

Supplemental Table 1. Primer sequences used in real-time quantitative PCR.

Sequence no.	Gene name	Primer sequence
1.	Human 18S	F-5'-GTAACCCGTTGAACCCATT-3' R-5'-CCATCCAATCGGTAGTAGCG-3'
2.	Human NLRP3	F-5'-CTTCTCTGATGAGGCCCAAG-3' R-5'-GCAGCAAACCTGGAAAGGAAG-3'
3.	Human ASC	F-5'-CTCTGTACGGGAAGGTCCTG-3' R-5'-TCCTCCACCAGGTAGGACTG-3'
4.	Human Caspase1	F-5'-TTCTGCTCTTCCACACC-3' R-5'-CTACCATCTGGCTGCTC-3'
5.	Human IL-1β	F-5'-AAGGGCTGCTTCCAAACCT-3' R-5'-ATACTGCCTGCCTGAAGCT-3'